NewGenIvf Group Limited closed a $2.5 million underwritten offering of Class A Ordinary Shares and Pre-Funded Warrants.
Quiver AI Summary
NewGenIvf Group Limited has successfully completed an underwritten offering, raising approximately $2.5 million through the sale of 71,428,570 Class A Ordinary Shares and pre-funded warrants. The company plans to use the proceeds for the commercialization of its advanced cytometry technology, investments in digital assets and AI, expansion of its real estate operations in the UAE, and other corporate purposes. A portion of the funds will also be allocated to repurchase existing debt. The offering was managed by Aegis Capital Corp. and is registered with the SEC. NewGenIvf Group Limited focuses on real estate, digital finance, and reproductive health solutions.
Potential Positives
- The company successfully raised approximately $2.5 million in gross proceeds through a firm commitment underwritten offering, enhancing its financial position.
- The proceeds will be utilized for commercialization and expansion of advanced cytometry technology and assisted reproductive services, indicating a focused growth strategy.
- The company plans to invest in strategic initiatives such as digital-asset and AI projects, and real estate interests in the UAE, reflecting diversification in its business model.
- The successful transaction and listing on the Nasdaq Capital Market could enhance investor confidence and market visibility for NewGenIvf Group Limited.
Potential Negatives
- The company raised only $2.5 million through the offering, which may indicate difficulties in attracting more substantial investment or market interest.
- The low offering price of $0.035 per Class A Ordinary Share could suggest a devaluation of the company's stock, potentially impacting investor confidence.
- Management retains broad discretion on how to use the net proceeds, which may raise concerns about the effectiveness and strategic planning of resource allocation.
FAQ
What is the amount raised in NewGenIvf's recent offering?
The recent offering raised approximately $2.5 million in gross proceeds for NewGenIvf Group Limited.
When did NewGenIvf's stock offering close?
The stock offering for NewGenIvf closed on November 20, 2026.
What will the proceeds from the offering be used for?
The proceeds will fund commercialization of technology, strategic investments, and general corporate purposes.
What types of securities were offered by NewGenIvf?
The offering included Class A Ordinary Shares and Pre-Funded Warrants to purchase additional Class A Ordinary Shares.
Who managed the NewGenIvf offering?
Aegis Capital Corp. acted as the sole book-running manager for NewGenIvf's offering.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NIVF Insider Trading Activity
$NIVF insiders have traded $NIVF stock on the open market 10 times in the past 6 months. Of those trades, 8 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $NIVF stock by insiders over the last 6 months:
- KONG YIU CHEUNG has made 4 purchases buying 3,722,223 shares for an estimated $4,163,334 and 0 sales.
- FINANCIAL LP HRT has made 4 purchases buying 200,290 shares for an estimated $193,918 and 2 sales selling 150,262 shares for an estimated $118,975.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NIVF Hedge Fund Activity
We have seen 3 institutional investors add shares of $NIVF stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANE STREET GROUP, LLC added 2,445 shares (+inf%) to their portfolio in Q3 2026, for an estimated $13,144
- HRT FINANCIAL LP removed 610 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $3,279
- UBS GROUP AG added 471 shares (+225.4%) to their portfolio in Q3 2026, for an estimated $2,532
- TOWER RESEARCH CAPITAL LLC (TRC) added 278 shares (+794.3%) to their portfolio in Q3 2026, for an estimated $1,494
- SBI SECURITIES CO., LTD. removed 115 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $19
- XTX TOPCO LTD removed 49 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $263
- MORGAN STANLEY removed 1 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $154
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
BANGKOK, Nov. 20, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a technology-driven, diversified growth company, today announced the closing of its previously announced firm commitment underwritten offering with gross proceeds to the Company of approximately $2.5 million, before deducting underwriting fees and other offering expenses payable by the Company.
The offering consisted of 71,428,570 Class A Ordinary Shares (or pre-funded warrants to purchase Class A Ordinary Shares in lieu thereof (the “Pre-Funded Warrants”)). At closing, the offering comprised 9,501,148 Class A Ordinary Shares and Pre-Funded Warrants to purchase up to 61,927,422 Class A Ordinary Shares. The offering price per Class A Ordinary Share was $0.035 (or $0.03499 for each Pre-Funded Warrant, which is equal to the offering price per Class A Ordinary Share sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Warrant sold in the offering, the number of Class A Ordinary Shares in the offering will be decreased on a one-for-one basis.
Aggregate gross proceeds to the Company were approximately $2.5 million. The transaction closed on November 20, 2026. The Company expects to use the net proceeds from the offering, together with its existing cash, for commercialization and expansion of the Nodexus advanced cytometry technology and our assisted reproductive services platform, further strategic investments in prediction-market and digital-asset/AI initiatives, our real estate interests in the UAE, and other general corporate purposes. Our management will retain broad discretion to apply these net proceeds. We will also apply approximately $625,000 of the gross proceeds of this offering to repurchase $584,112 in principal amount of the Exchange Note. The Company’s Class A Ordinary Shares are listed on the Nasdaq Capital Market under the symbol “NIVF”.
Aegis Capital Corp. acted as the sole book-running manager for the offering. Han Kun Law Offices LLP acted as U.S. counsel to the Company. Kaufman & Canoles, P.C. acted as U.S. counsel to Aegis Capital Corp.
The offering was made pursuant to an effective shelf registration statement on Form F-3 (No. 333-299649) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on November 12, 2026. A final prospectus supplement and accompanying prospectus describing the terms of the offering have been filed with the SEC and are available on the SEC’s website located at www.sec.gov . Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at [email protected], or by telephone at +1 (212) 813-1010.
Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and the offering.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About NewGenIvf Group Limited
NewGenIvf Group Limited is a technology-forward, diversified growth company pursuing opportunities across real estate development, digital asset innovation, and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah, United Arab Emirates; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. The Company’s legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the anticipated use of proceeds from the offering, the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. For a discussion of the risks and uncertainties that could cause actual results to differ materially, see the section entitled “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 and in the final prospectus supplement relating to the offering. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Investor Contact:
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: [email protected]